Evidence map›Paper›PMID 38202656›Full record

ArticleMolecules (Basel, Switzerland)2023

Antileishmanial Effect of 1,5- and 1,8-Substituted Fused Naphthyridines.

Estela Melcón-Fernandez, Endika Martín-Encinas, Francisco Palacios, Gulio Galli, Rosa M Reguera, María Martínez-Valladares, Rafael Balaña-Fouce, Concepción Alonso, Yolanda Pérez-Pertejo

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Antimicrobial Activity of Naphthyridine Derivatives.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Estela Melcón-FernandezDepartamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24071 León, Spain.ORCID 0000-0002-9663-060X
Endika Martín-EncinasDepartamento de Química Orgánica I, Facultad de Farmacia, Lascaray Research Center, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.
Francisco PalaciosDepartamento de Química Orgánica I, Facultad de Farmacia, Lascaray Research Center, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.
Gulio GalliDepartamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24071 León, Spain.ORCID 0000-0001-6854-5507
Rosa M RegueraDepartamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24071 León, Spain.ORCID 0000-0001-9148-2997
María Martínez-ValladaresDepartamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24071 León, Spain.ORCID 0000-0002-3723-1895
Rafael Balaña-FouceDepartamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24071 León, Spain.ORCID 0000-0003-0418-6116
Concepción AlonsoDepartamento de Química Orgánica I, Facultad de Farmacia, Lascaray Research Center, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.ORCID 0000-0003-0866-3493
Yolanda Pérez-PertejoDepartamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24071 León, Spain.
Universidad de León · ESUniversity of the Basque Country · ES

Funding

Basque Government IT1701-22Ministerio de Ciencia e Innovación PID2021-122558OB-I00Vital Foundation VITAL23/28
6 · The paper itself

Abstract

In the absence of a vaccine, there is a need to find new drugs for the treatment of neglected tropical diseases, such as leishmaniasis, that can overcome the many drawbacks of those currently used. These disadvantages include cost, the need to maintain a cold chain, the route of administration, the associated adverse effects and the generation of resistance. In this work we have evaluated the antileishmanial effect of 1,5- and 1,8-substituted fused naphthyridines through in vitro and ex vivo assays, using genetically modified axenic and intramacrophagic

Indexed as

Antiprotozoal AgentsDrug-Related Side Effects and Adverse ReactionsAdministration, OralAnimalsBiological AssayMammalsMiceNaphthyridinesAntiprotozoal AgentsNaphthyridinesfused 1,5-naphthyridinesfused 1,8-naphthyridinesintramacrophagic Leishmania parasitesmouse intestinal organoidsvisceral leishmaniasis

Identifiers

PMID38202656
PMCPMC10780244
OpenAlexW4390107292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.